Rosen Firm's contact information, obviously posted here only as a service so that anyone who wants to can join the class action suit, and for no other reason whatsoever hahaha. By the way, apparently although they claim to have filed a suit, today's company press release implied that CTIX had not in fact been served -- so that is something else for the complaint to the professional responsibility board. Anyone who is calling, please be sure to use their toll-free number, which incurs charges to THEM.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
kchan@rosenlegal.com
www.rosenlegal.com
The Rosen Law Firm announces that it has filed a class action lawsuit on behalf of purchasers of Cellceutix Corporation (OTC: CTIX) securities from May 10, 2013 through August 6, 2015, resulting from Cellceutix misrepresenting the efficacy of its drug candidates Brilacidin and Kevetrin, and Krishna Menon's credentials.
If you purchased Cellceutix securities from May 10, 2013 through August 6, 2015, and would like to join the action, please click "Join This Class Action" above.
Press Release
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Cellceutix Corporation – CTIX
New York, N.Y., September 11, 2015. Rosen Law Firm, a global investor rights law firm, announces that it has filed a class action lawsuit on behalf of purchasers of Cellceutix Corporation (OTC: CTIX) securities from May 10, 2013 through August 6, 2015, all dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Cellceutix investors under the federal securities laws.
To join the Cellceutix class action, go to the firm’s website at http://www.rosenlegal.com/cases-689.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action. The lawsuit is pending in U.S. District Court for the Southern District of New York.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants issued materially false and misleading statements to investors and/or failed to disclose that: (1) Cellceutix’s antibiotic drug candidate Brilacidin is ineffective; (2) Cellceutix’s anti-cancer drug candidate Kevetrin does not activate p-53 gene, which suppresses tumors; (3) Cellceutix’s co-founder and Director, Krishna Menon, did not earn his PhD in Pharmacology from Harvard University; and (4) as a result, Cellceutix’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 10, 2015. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://www.rosenlegal.com/cases-689.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
kchan@rosenlegal.com
www.rosenlegal.com
The Rosen Law Firm announces that it has filed a class action lawsuit on behalf of purchasers of Cellceutix Corporation (OTC: CTIX) securities from May 10, 2013 through August 6, 2015, resulting from Cellceutix misrepresenting the efficacy of its drug candidates Brilacidin and Kevetrin, and Krishna Menon's credentials.
If you purchased Cellceutix securities from May 10, 2013 through August 6, 2015, and would like to join the action, please click "Join This Class Action" above.
Press Release
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Cellceutix Corporation – CTIX
New York, N.Y., September 11, 2015. Rosen Law Firm, a global investor rights law firm, announces that it has filed a class action lawsuit on behalf of purchasers of Cellceutix Corporation (OTC: CTIX) securities from May 10, 2013 through August 6, 2015, all dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Cellceutix investors under the federal securities laws.
To join the Cellceutix class action, go to the firm’s website at http://www.rosenlegal.com/cases-689.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action. The lawsuit is pending in U.S. District Court for the Southern District of New York.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants issued materially false and misleading statements to investors and/or failed to disclose that: (1) Cellceutix’s antibiotic drug candidate Brilacidin is ineffective; (2) Cellceutix’s anti-cancer drug candidate Kevetrin does not activate p-53 gene, which suppresses tumors; (3) Cellceutix’s co-founder and Director, Krishna Menon, did not earn his PhD in Pharmacology from Harvard University; and (4) as a result, Cellceutix’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 10, 2015. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://www.rosenlegal.com/cases-689.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
